Abstract
Early results of a phase I evaluation of TAK-228 (TORC 1/2 inhibitor) in combination with TAK-117 (PI3K alpha inhibitor) and paclitaxel in advanced gynecologic malignancies and metastatic breast cancer
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
